MEI Pharma Acquires Rights to Cancer Drug

MEI Pharma, a San Diego-based drugmaker, has acquired global rights to Pathway Therapeutics’ PWDT143, a drug that has not yet been proven to inhibit the growth of blood cancer cells.
San Diego Business Journal